Home » Authors » Nuala Moran

Nuala Moran

Articles

ARTICLES

Abbott Seeks Approvals For CAT’s Monoclonal Antibody

April 17, 2002

Paradigm, Genmab Collaborate In Therapeutic Antibodies Deal

April 17, 2002

Abbott Seeks Approvals For CAT’s Monoclonal Antibody

April 17, 2002

Paradigm, Genmab Collaborate In Therapeutic Antibodies Deal

April 17, 2002

RiboTargets Signs With ICR To Develop Inhibitors Of HSP90

April 10, 2002

Ark IPO Aims For £40M, Looks To End UK Public Offering Dry Spell

April 10, 2002

RiboTargets Signs With ICR To Develop Inhibitors Of HSP90

April 10, 2002

Ark IPO Aims For £40M, Looks To End UK Public Offering Dry Spell

April 10, 2002

Celltech Signs Drug Conjugate Deal With Seattle Genetics

April 3, 2002

Astex, Aventis Collaborate On Drug-Metabolizing Enzymes

April 3, 2002

View All Articles by Nuala Moran

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...